Blanc Frédéric, Mahmoudi Rachid, Jonveaux Thérèse, Galmiche Jean, Chopard Gilles, Cretin Benjamin, Demuynck Catherine, Martin-Hunyadi Catherine, Philippi Nathalie, Sellal François, Michel Jean-Marc, Tio Gregory, Stackfleth Melanie, Vandel Pierre, Magnin Eloi, Novella Jean-Luc, Kaltenbach Georges, Benetos Athanase, Sauleau Erik A
Memory Resource and Research Centre (CM2R), Geriatrics Day Hospital, Geriatrics Department, University Hospital of Strasbourg, 21 rue David Richard, 67091, Strasbourg Cedex, France.
University of Strasbourg and French National Centre for Scientific Research (CNRS), ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS)/Neurocrypto, Strasbourg, France.
Alzheimers Res Ther. 2017 Jun 27;9(1):47. doi: 10.1186/s13195-017-0272-8.
Longitudinal studies of dementia with Lewy bodies (DLB) are rare. Clinically, DLB is usually considered to worsen into Alzheimer's disease (AD). The aim of our study was to compare the rate of the cognitive decline in DLB, AD, and the association of the two diseases (AD + DLB).
Using the Regional Network for Diagnostic Aid and Management of Patients with Cognitive Impairment database, which includes all the patients seen at all memory clinics (medical consultation and day hospitals) in four French regions, and beta regression, we compared the longitudinal the Mini-Mental State Examination scores of 1159 patients with AD (n = 1000), DLB (n = 131) and AD + DLB (association of the two) (n = 28) during follow-up of at least 4 years.
The mean follow-up of the patients was 5.88 years. Using beta regression without propensity scores, the comparison of the decline of patients with AD and patients with DLB did not show a significant difference, but the decline of patients with AD + DLB was worse than that of either patients with DLB (P = 0.006) or patients with AD (P < 0.001). Using beta regression weighted by a propensity score, comparison of patients with AD and patients with DLB showed a faster decline for patients with DLB (P < 0.001). The comparison of the decline of patients with AD + DLB with that of patients with DLB (P < 0.001) and patients with AD (P < 0.001) showed that the decline was clearly worse in the patients with dual disease.
Whatever the analysis, the rate of decline is faster in patients with AD + DLB dual disease. The identification of such patients is important to enable clinicians to optimise treatment and care and to better inform and help patients and caregivers.
路易体痴呆(DLB)的纵向研究很少见。临床上,DLB通常被认为会恶化为阿尔茨海默病(AD)。我们研究的目的是比较DLB、AD以及两种疾病的关联(AD+DLB)患者的认知衰退率。
利用认知障碍患者诊断辅助与管理区域网络数据库,该数据库包含法国四个地区所有记忆诊所(医学咨询和日间医院)诊治的所有患者,并采用β回归分析,我们比较了1159例AD患者(n = 1000)、DLB患者(n = 131)和AD+DLB(两种疾病的关联)患者(n = 28)在至少4年随访期间的纵向简易精神状态检查得分。
患者的平均随访时间为5.88年。使用未加权倾向得分的β回归分析,AD患者和DLB患者衰退情况的比较未显示出显著差异,但AD+DLB患者的衰退情况比DLB患者(P = 0.006)和AD患者(P < 0.001)更严重。使用倾向得分加权的β回归分析,AD患者和DLB患者的比较显示DLB患者衰退更快(P < 0.001)。AD+DLB患者与DLB患者(P < 0.001)和AD患者(P < 0.001)衰退情况的比较表明,双重疾病患者的衰退明显更严重。
无论采用何种分析方法,AD+DLB双重疾病患者的衰退率都更快。识别这类患者对于临床医生优化治疗和护理以及更好地为患者和护理人员提供信息和帮助非常重要。